Back to dashboard
CommercialCoverageMedium impact

05.00.77e, Subcutaneous Implantable Cardioverter Defibrillator (S-ICD) for Treating Life-threatening Ventricular Tachyarrhythmia

Independence Blue Cross·Cardiology, Cardiothoracic Surgery·Coding
Effective date
Apr 2, 2025
We identified it
Jun 19, 2026
Days to comply

Summary

IBX has reissued policy 05.00.77e regarding coverage for Subcutaneous Implantable Cardioverter Defibrillator (S-ICD) procedures for treating life-threatening ventricular tachyarrhythmia. This is a commercial policy update that will take effect April 2, 2025.

Action Required

Action needed
By April 2, 2025: Review the complete policy document at the provided URL to identify specific changes to S-ICD coverage requirements, billing procedures, or documentation standards. Update billing protocols and staff training accordingly for commercial IBX plans covering S-ICD procedures.